Ryan Haumschild, PharmD, MS, MBA, CPEL, vice president of ambulatory pharmacy at Emory Healthcare Winship Cancer Institute, provided valuable insights into the evolving treatment modalities in multiple myeloma (MM) at the Oncology Pharmacists Connect 2024 meeting. In the interview, Haumschild discusses advancements in new treatment approaches, the effectiveness of combination therapies, overcoming treatment resistance, and management of common adverse effects associated with new lines of treatment. Can you discuss the evolving treatment modalities in MM and how do these new treatments compare with traditional approaches in terms of efficacy and patient outcomes? So, in myeloma, we've seen a lot of changes recently.
And so that's been exciting innovation for our patients, not only new therapies, but the way we're combining the different treatment options. So historically, everyone becomes transplant or transplant, ineligible, either standard or high risk. And we'd start with maybe a double [inaudible].
And then from there, do some combination therapies depending on [the] mutation and resistance that would occur. We are still looking at transplant eligible and non-transplant eligible, but really innovating. We're bringing more effective therapies up earlier and lines of treatment.
So instead of waiting for relapse refractory to introduce some different treatments, now we're saying, “what do we do if we move that earlier?” So now starting maybe triplets or quadruplets in the.